bluebird bio sells second priority review voucher for $95 million

bluebird bio

6 January 2023 - bluebird bio today announced that it has entered into a definitive agreement to sell its second rare paediatric disease priority review voucher for $95 million.

bluebird bio was granted two priority review vouchers upon the US FDA approvals of Zynteglo (betibeglogene autotemcel) for the treatment of beta thalassaemia in adult and paediatric patients requiring regular red blood cell transfusions and Skysona (elivaldogene autotemcel) for the treatment of early, active cerebral adrenoleukodystrophy, on 17 August 2022 and 16 September 2022 respectively. 

On 29 December 2022, bluebird closed the sale of its first voucher for $102 million.

Read bluebird bio press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

US , Priority review